This article was originally published in The Gray Sheet
Executive SummaryEliminates 775 jobs from its Connecticut and Puerto Rico operations in a cost-cutting move, the firm says Oct. 30. Two-thirds (490) of the reductions are voluntary and affect primarily manufacturing positions, while the remaining 285 layoffs involve supervisory and managerial staff at USSC, which was recently bought by Tyco International for $3.3 bil. ("The Gray Sheet" June 1, p. 3). No cuts in the firm's sales force are made. Future reductions at USSC's non-Connecticut operations also are expected, according to the firm, which plans over the next 15 months to consolidate its Norwalk and North Haven, Connecticut, facilities in a single campus at North Haven
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.